Receive our newsletter – data, insights and analysis delivered to you
July 12, 2009

InNexus Partners with Genhelix for New Product Development

InNexus and Genhelix have signed a Letter of Intent to set the stage for a planned strategic collaboration, to focus on developing novel antibodies engineered with InNexus' DXL technology. The research and licensing agreement between the collaborators is expected to be complete later i

By cms admin

InNexus and Genhelix have signed a Letter of Intent to set the stage for a planned strategic collaboration, to focus on developing novel antibodies engineered with InNexus’ DXL technology.

The research and licensing agreement between the collaborators is expected to be complete later in 2009.

InNexus would conduct preclinical development for a DXL therapeutic against an undisclosed target, with Genhelix providing GMP production and commercial manufacturing.

InNexus CEO Jeff Morhet said that the organisations are poised to strategically collaborate as partners focused on the development of new products, while maintaining their respective business competencies.

“This collaboration provides significant opportunities for both companies, and represents a creative approach to partnering that brings resources and capabilities together while the partners stay focused,” Morhet said.

News of the planned alliance follows InNexus’ recently announced meeting with the US Food and Drug Administration (FDA).

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

The FDA expressed clear support for the company’s product development plans, following a comprehensive review of the proposed clinical pathway for its lead preclinical candidate, DXL625 (CD20).

The FDA also provided a manufacturing exception approval allowing InNexus to manufacture all clinical material needed for DXL625’s Phase I human trial.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU